Active Ingredient History
Clomiphene (CLOMID®) is a triphenyl ethylene stilbene derivative which is an estrogen agonist or antagonist depending on the target tissue. It is an orally administered, nonsteroidal, ovulatory stimulant. Clomiphene (CLOMID®) is a mixture of two geometric isomers [cis (zuclomiphene) and trans (enclomiphene)] containing between 30% and 50% of the cis-isomer. Clomiphene (CLOMID®) initiates a series of endocrine events culminating in a preovulatory gonadotropin surge and subsequent follicular rupture. The first endocrine event in response to a course of clomiphene therapy is an increase in the release of pituitary gonadotropins. This initiates steroidogenesis and folliculogenesis, resulting in growth of the ovarian follicle and an increase in the circulating level of estradiol. Following ovulation, plasma progesterone and estradiol rise and fall as they would in a normal ovulatory cycle. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Infertility, Female (approved 1967)
Acromegaly (Phase 2)
Allergy and Immunology (Phase 1/Phase 2)
Androgens (Phase 2)
Anovulation (Phase 4)
Clomiphene (Phase 4)
Corpus Luteum (Phase 2)
Cytochrome P-450 CYP2D6 (Phase 1)
Cytochrome P-450 CYP3A (Phase 1)
Diabetes Mellitus, Type 2 (Phase 2)
Drugs, Investigational (Phase 4)
Endocrine System Diseases (Phase 1/Phase 2)
Eunuchism (Phase 2)
Fertilization in Vitro (Phase 4)
Gonadal Disorders (Phase 1/Phase 2)
Gonadotropin-Releasing Hormone (Phase 4)
Hyperandrogenism (Phase 3)
Hyperprolactinemia (Phase 2)
Hypogonadism (Phase 2)
Infertility (Phase 4)
Infertility, Female (Phase 4)
Infertility, Male (Phase 3)
Inositol (Phase 4)
Insulin Resistance (Phase 3)
Leiomyoma (Phase 1)
Obesity (Phase 2)
Obsessive-Compulsive Disorder (Phase 4)
Opioid-Related Disorders (Phase 2)
Ovarian Diseases (Phase 4)
Ovarian Follicle (Phase 2)
Ovulation (Phase 4)
Ovulation Induction (Phase 4)
Pioglitazone (Early Phase 1)
Polycystic Ovary Syndrome (Phase 4)
Pregnancy (Phase 4)
Primary Ovarian Insufficiency (Phase 2)
Prolactinoma (Phase 2)
Reproductive Health (Phase 2)
Rotator Cuff Injuries (Phase 2)
Substance Abuse, Oral (Phase 1)
Testosterone (Phase 2)
Uterine Diseases (Phase 2)
Vitamin D Deficiency (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
